Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Zongertinib demonstrated durable efficacy in patients with pretreated advanced HER2-mutant non–small cell lung cancer.

Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC 

Second-line lenvatinib had clinically meaningful efficacy in patients with advanced HCC after progression on atezolizumab plus bevacizumab.

Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab

The phase 3 TROPiCS-04 study missed its primary end point of improved OS with sacituzumab govitecan vs chemotherapy in patients with urothelial cancer.

Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma

Rates of invasive cancer were noninferior when patients with low-risk ductal carcinoma in situ received active monitoring vs guideline concordant care. 

Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages 

 social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: 

Adding dostarlimab to chemotherapy and niraparib maintenance improved progression-free survival in first-line advanced ovarian cancer.

Addition of Dostarlimab to Chemo and Niraparib Maintenance Boosts PFS in Advanced Ovarian Cancer

 as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: 

The addition of pegcrisantaspase to venetoclax may overcome resistance to prior BCL-2 inhibitor–based regimens for patients with relapsed/refractory AML. 

Venetoclax Plus PegC May Overcome Resistance to Prior BCL-2 Inhibitors in R/R AML 

The FDA has approved encorafenib plus cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation.

FDA Grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer  

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication 

, aiding in all aspects of the publication process, as well as content for OncLive.com.

Retifanlimab represents a promising agent in the squamous cell anal carcinoma field and additional research is needed to improve outcomes for patients.

Filling Unmet Needs in SCAC Is Key as Incidence Rates Are Rising 

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

Optimizing Therapy for Patients with Acute and Chronic Graft-Versus-Host Disease (GvHD)

OncLive Peer Exchange® 

Videos

Moderator Michael Bishop, MD leads a discussion with panelists Hannah Choe, MD, Doris M. Ponce, MD, and Bart L Scott, MD, concerning recent updates in the prevention, diagnosis, and treatment of Graft-Versus-Host Disease.

Moderator Michael Bishop, MD introduces expert panelists and leads an overview of Graft-Versus-Host Disease, covering the differences between chronic and acute conditions, how GvHD is typically diagnosed, and GvHD risk assessment. 

Understanding Chronic and Acute Graft-Versus-Host Disease Presentation and Diagnosis

Panelists Hannah Choe, MD, and Bart L Scott, MD share insights concerning prophylaxis in Graft-Versus-Host Disease, including key study data and current standards of care as well as discuss the potential role of biomarkers in GvHD. 

Improving Patient Outcomes: Prophylactic Options in Graft-Versus-Host Disease

Subject-matter experts delve into the diagnosis, risk assessment, and treatment selection process for acute GvHD, emphasizing differentiation of refractory disease.

Optimal First-Line Treatment Approaches for Acute GvHD

Treatment options for steroid refractory acute GvHD, including ruxolitinib efficacy and NCCN guideline adherence, take center stage in the discussion.

Treatment Options in Steroid-Refractory Acute GvHD

Supportive care measures for acute GvHD are explored, highlighting strategies to manage symptoms and improve patient well-being.

Enhancing Patient Care in Acute GvHD: Supportive Measures

Experienced clinicians discuss the future of acute GvHD treatment, focusing on gaps in patient care and potential therapy options.

Advancements and Promising Directions in Acute GvHD

Insights on treatment strategies and goals for initial chronic GvHD management, including treatment selection rationale and dosing.

Establishing Treatment Objectives for Chronic GvHD: First-Line Strategies

Exploring FDA-approved treatment options for patients with chronic GvHD, with a focus on trial data and adverse effects. 

A Comprehensive Look at Initial Treatment Options for Chronic GvHD

Clinical pearls for community oncologists regarding treatment selection and sequencing in chronic GvHD patients.

Data-Driven Treatment Selection for Patients with Chronic GvHD

Addressing patient monitoring in chronic GvHD, including therapy adjustment indicators and frequency.

Remote Patient Monitoring and Supportive Care Measures in Chronic GvHD

Expert panelists share final thoughts concerning the future of chronic GvHD treatment, highlighting unmet needs, ongoing trials, and promising therapies. 

Data-Driven Treatment Selection for Patients with Chronic GvHD

EP: 1.Understanding Chronic and Acute Graft-Versus-Host Disease Presentation and Diagnosis

EP: 2.Improving Patient Outcomes: Prophylactic Options in Graft-Versus-Host Disease

EP: 3.Optimal First-Line Treatment Approaches for Acute GvHD

EP: 4.Treatment Options in Steroid-Refractory Acute GvHD

EP: 5.Enhancing Patient Care in Acute GvHD: Supportive Measures

EP: 6.Advancements and Promising Directions in Acute GvHD

EP: 7.Establishing Treatment Objectives for Chronic GvHD: First-Line Strategies

EP: 8.A Comprehensive Look at Initial Treatment Options for Chronic GvHD

EP: 9.Data-Driven Treatment Selection for Patients with Chronic GvHD

EP: 10.Remote Patient Monitoring and Supportive Care Measures in Chronic GvHD

EP: 11.The Future of Chronic GvHD Treatment

Latest Conference Coverage